-
Most Recent
Search Results
240 results for abv
The AI Stock ‘Peak Spending’ Panic Just Lost Its ‘Ehrlich Bet’
Luke Lango breaks down the earnings that dismantled the peak spending narrative, what the July CPI print means for rates, and why the AI stock…
Why The Fed’s Balancing Act Is Tilting in Wall Street’s Favor
In today’s Market 360, let’s take a closer look at the latest inflation numbers, what they mean for the Fed and the stock market –…
The Painful Mistake After Finding a 10-Bagger
AI is moving too quickly. The potential rewards are becoming too large. And the divide between the companies benefiting from this revolution and those left…
The 680% Winner You Should Trim Today
Bears’ math problem… why falling valuations point to more upside… the 680% winner to trim… how to position for AI today… Louis Navellier on why…
ABM’s Dividend Increase Won’t Keep it Above $30
This morning I am recommending a bearish trade on ABM Industries, Inc. (NYSE:ABM), a provider of facility services like parking, janitorial services and building and…
Trade of the Day: AbbVie (ABBV)
In 2017, Humira raked in $18.9 billion in sales for AbbVie (ABBV) and, according to the company’s latest earnings announcement, that sales rate grew by…
4 Catalysts That Could Put Space Stocks Back in Orbit in 2026
Space stocks have four new catalysts in 2026 – policy execution, SpaceX validation, orbital compute, and a collapsing launch cost curve.
Four Actionable Stock Ideas From a Legendary Investor
In today’s Digest, Brian Hunt highlights several themes he’s watching closely, shares a handful of stocks that have caught his attention, and explains what recent…
Strong Buy for AbbVie (ABBV) This Week
AbbVie (ABBV) remains a Strong Buy this week based on the most current relative pricing of its shares and analysis.
Strong Buy for AbbVie (ABBV) This Week
The Strong Buy for AbbVie (ABBV) this week is based on the latest stock market rankings, and relative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $114.93, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
Strong Buy for AbbVie (ABBV) This Week
At $118.94, AbbVie (ABBV) a Strong Buy based on the most recent SEC filings, and comparative pricing of its shares.
How My “Against-the-Grain” Approach Finds AI’s Hidden Winners
In today’s Smart Money, I’ll show you why the raw materials behind the AI boom could be one of its most overlooked opportunities. Then, like…
Microsoft Has the AI Backlog, But This Company Has the Returns
Let’s take a look at why Wall Street may be celebrating AI profits before they actually arrive. Then, I’ll share one company that is already…
AbbVie (ABBV) a Buy on Healthy Earnings Momentum
AbbVie Inc (NYSE:ABBV) is ranked as a Buy using the approach to investing of Louis Navellier and his Portfolio Grader stock evaluator. This represents no…
AbbVie (ABBV) a Buy on Strong Quant Score
Currently, AbbVie Inc (NYSE:ABBV) has a Buy using the methodology of Louis Navellier for investing and his Portfolio Grader stock evaluator. ABBV has maintained this…
AbbVie (ABBV) a Buy on Robust Quant Score
AbbVie Inc (NYSE:ABBV) is a $147.1 billion in market value member of the Biotechnology GICS industry group where the stock’s current Portfolio Grader score places…
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $114.56
AbbVie (ABBV) a Strong Buy at $114.56 based on the most current analysis, and comparative pricing of its shares.
AbbVie (ABBV) a Strong Buy at $117.98
At $117.98, AbbVie (ABBV) a Strong Buy based on the latest SEC filings, and comparative pricing of its shares.
AbbVie Inc: ABBV Stock Is a Prescription for Profits
Investors and traders should be positioning themselves in AbbVie stock. This trade on ABBV will help you limit earnings volatility while allowing you to enjoy…
AbbVie Inc (ABBV) Is About to Steamroll the Competition
Good news for AbbVie (ABBV) shareholders: The pharmaceutical company just entered the Hepatitis C. market, while reinforcing its position in the psoriasis area. Given ABBV’s…
Trade of the Day: AbbVie Inc. (NYSE:ABBV)
AbbVie has a great opportunity for growth in developing and commercialize BioArctic’s treatment platform for neurodegenerative diseases.
7 – 10 of 240 results
